| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
BASIC SCIENCE |



*INSERM U388, IFR31, Institut Louis Bugnard, CHU Rangueil, Toulouse, France;
Department of Pathology, CHU Rangueil, Toulouse, France;
Laboratory of Biochemistry, CHU Rangueil, Toulouse, France;
INSERM U-466, IFR-31, University Paul Sabatier, Bat L3, CHU Rangueil, Toulouse, France; and ¶Cardiovascular-Thrombosis Research Department, Sanofi-Synthélabo Research, Toulouse, France.
Correspondence to Dr. Angelo Parini, INSERM U388, Institut Louis Bugnard, CHU Rangueil, Bat. L3, 31403 Toulouse Cedex 4, France. Phone: +33-561322622; Fax: +33-562172554; E-mail: parini{at}toulouse.inserm.fr
The peripheral benzodiazepine receptor (PBR) is a critical component of the mitochondrial permeability transition pore, which is involved in the regulation of cell death. In the present study we investigated the role of PBR in the regulation of signaling pathways leading to apoptotic and necrotic damage and renal dysfunction in a rat model of ischemia-reperfusion. Renal ischemia-reperfusion led to extended tubular apoptosis and necrosis that were associated with peroxidative damage, high levels of proapoptotic Bax expression, and low levels of antiapoptotic Bcl-2 expression, cleavage of death substrate, poly(ADP-ribose) polymerase (PARP), and activation of a key effector of apoptosis, caspase-3. Rat pretreatment with a novel PBR antagonist, SSR180575, significantly decreased postreperfusion oxidative stress and tubular apoptosis and necrosis. This effect was associated with inhibition of caspase-3 activation and PARP cleavage, upregulation of Bcl-2, and downregulation of Bax. Furthermore, inhibition of PBR accelerated the recovery of normal renal function, as assessed by measurement of levels of plasma creatinine and blood urea nitrogen. These findings reveal a role for PBR as a modulator of necrotic and apoptotic cell death induced by ischemia-reperfusion and suggest that regulation of PBR may provide new therapeutic implications for the prevention of acute renal failure.
This article has been cited by other articles:
![]() |
C. Doucet, S. Milin, F. Favreau, T. Desurmont, E. Manguy, W. Hebrard, Y. Yamamoto, G. Mauco, M. Eugene, V. Papadopoulos, et al. A p38 mitogen-activated protein kinase inhibitor protects against renal damage in a non-heart-beating donor model Am J Physiol Renal Physiol, July 1, 2008; 295(1): F179 - F191. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mazzinghi, E. Ronconi, E. Lazzeri, C. Sagrinati, L. Ballerini, M. L. Angelotti, E. Parente, R. Mancina, G. S. Netti, F. Becherucci, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homingof human renal progenitor cells J. Exp. Med., February 18, 2008; 205(2): 479 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Yang, L. Martin-Hawver, C. Woodall, A. Thomas, N. Qureshi, D. Morrison, and C. Van Way III Administration of Glutamine After Hemorrhagic Shock Restores Cellular Energy, Reduces Cell Apoptosis and Damage, and Increases Survival JPEN J Parenter Enteral Nutr, March 1, 2007; 31(2): 94 - 100. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673